LearnGlossaryMarketStocksSuperinvestorsSign in

ANTX

AN2 Therapeutics, Inc.

Healthcare · $183M market cap

Verdict

We can't put a fair value on ANTX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-42.4% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-64.7%✗

Follow ANTX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: 1 open-market purchase worth $12K and 7 sales worth $106K. Why purchases matter

Purchases

FitzPatrick Margaret M

director · 2026-09-01

Bought

$12K

Sales

Readnour Robin Shane

director · 2026-09-09

Sold

$4K

Readnour Robin Shane

director · 2026-09-09

Sold

$3K

Readnour Robin Shane

director · 2026-09-08

Sold

$32K

Readnour Robin Shane

director · 2026-09-08

Sold

$28K

Readnour Robin Shane

director · 2026-09-03

Sold

$20K

Show all 7 sales

Readnour Robin Shane

director · 2026-09-03

Sold

$17K

Williams Sarah Joanne

Principal Accounting Officer · 2026-09-01

Sold

$2K

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works